Article Image

IPFS News Link • Drugs and Medications

The Extraordinary Hypocrisy of Molnupiravir

• James Lyons-Weiler - Popular Rationalism

Trigger alert: This article may upset those who care about other human beings.

Molnupiravir (mull-noo-'peer-aveer) is the talk of the town, belle of the ball in the press. "Game changer" is the word on the street, according to a message to Science Insider:

"Molnupiravir is unquestionably a game changer! The large effect size, and the ease of administration change the paradigm of mild COVID-19 treatment with a potential to reduce COVID-19 death rates." See: Science Magazine

The hype even included Fauci going on in an interview about how the idea that molnupiravir is so effective that the vaccine won' t be needed.

"That's such a false narrative" Fauci aped at the camera.

What's all the excitement & hype about?

Well for one, Merck reported no deaths in the molnupirvir group, but there were eight deaths in the placebo group.

Great news, right?

Hold on there. This is an interim analysis. On non-hospitalized patients. (See the Phase 3 MOVe-OUT trial record at ClinicalTrials.gov)

Why, when the litany of studies have been published on the efficacy of off-label use of hydroxychloroquine and ivermectin, has the media been silent or hostile to the published studies? When meta-analyses find that the studies - both randomized clinical trials and observational studies - spanning the range of prophylaxis, mild, moderate and severe COVID-19 support immediate adoption for early treatment using ivermectin especially - why in the world is Merck's molnupirvir interim analysis given the spotlight?

Slow Down, People. The Molnupirvir Study is ONE Study (And It's Not Even a Study) In Non-Hospitalized People Without HIV, Hepatitis or Liver Disease. And the Hospitalized Patients - They're Found in A SECOND, BURIED Study.

Before we get too excited about molnupirvir, let's remember that there are 29 studies on ivermectin and 32 studies on hydroxychloroquine totaling over 26,000 and 54,000 patients combined, respectively.

(See https://c19early.com, https://hcqmeta.com, and https://ivmmeta.com).

Merck's non-peer-reviewed molnupirvir interim analysis report study? Only 775 patients.


Home Grown Food